close

Fundraisings and IPOs

Date: 2011-10-26

Type of information: Fundraising

Company: Curetis (Germany)

Investors:

Amount: Expansion of the financing round by € 9.6 million

Funding type:

Planned used:

The proceeds enable Curetis to be fully financed for its upcoming clinical trials in the EU and the US, its planned 2012 European market launch of the Unyvero® platform and pneumonia application and the FDA filing and clearance in 2012/13. The funds will also be used to develop cartridges for additional indications, e.g. for surgical site infection and tuberculosis.

Others:

Curetis AG, a molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, has announced the expansion of its Series A financing round by € 9.6 million. The additional funds increase the round to a total of €34.1 million and the total capital raised to date to € 36.6 million. The financing was led by Forbion Capital Partners together with Roche Venture Fund. Holger Reithinger, Partner at Forbion Capital Partners, has joined Curetis\' Board of Directors. Roche will get an observer seat on the Board of Directors.

Curetis AG has developed the versatile Unyvero™ instrument platform which handles disease-specific disposable cartridges for the analysis of various marker panels, covering both pathogens and antibiotic resistance genes. The Unyvero™ platform combines a fully automated sample preparation working with a comprehensive range of native clinical sample types, with isolation, amplification and highly multiplexed detection of DNA. The simplified, automated and uniform work flow enables testing at the point of need, eliminates operator-induced variations and ensures high-quality results in a short time frame. Clinically relevant information is available within three hours to support an informed therapy decision as early as possible.

The first application, Unyvero™ P50, is a solution for comprehensive pneumonia testing and simultaneously analyses 39 DNA targets. It has successfully completed extensive pre-clinical testing, is about to enter into pivotal clinical trials towards regulatory clearance and is scheduled to enter the European market as a CE-marked device in 2012. Cartridges for further applications, e.g. for surgical site infections, blood stream infections and tuberculosis, are in preparation.

Therapeutic area: Infectious diseases

Is general: Yes